Predictors of successful cardioversion of recent-onset atrial fibrillation to sinus rhythm with orally inhaled flecainide

Abstract Background Height, weight, and body mass index (BMI) are well established risk factors for atrial fibrillation (AF) but whether they also predictors of successful pharmacological cardioversion AF is unknown. Data from the open-label INSTANT study flecainide acetate oral inhalation solution (FlecIH) acute recent-onset symptomatic were examined to determine if these anthropometric measures sinus rhythm (SR) with FlecIH. Methods Logistic regression was performed on a broad array patient disease characteristics identify success at 90 minutes post-dose, potential interactions by boundary restriction analysis. presented patients receiving 120 mg Results 81 (32.1% female) mean age 59.8 years (range: 26.0, 84.0) included in This cohort had weight 87 kg 57, 150), height 180 cm 156, 199), BMI 26.8 kg/m2 17.2, 37.9). A logistic model identified height, as significant (p<0.01) analysis revealed negative correlation between conversion rate across entire dataset (see Figure 1). Clinically rates observed values that considered normal (BMI <25 = 53%; 95% CI: 36, 70), overweight ≥25 <30 47%; 29, 64), obese ≥30 <35 43%; 17, 69); however, none severely ≥35 mg/m2) their successfully converted 2). Conclusions Successful recent onset FlecIH normal, overweight, kg/m2; decreases increasing BMI. Further evaluation dosing warranted. Funding Acknowledgement Type funding sources: Private company. Main source(s): InCarda Therapeutics